Published online Jan 15, 2025. doi: 10.4251/wjgo.v17.i1.98433
Revised: October 10, 2024
Accepted: November 4, 2024
Published online: January 15, 2025
Processing time: 169 Days and 5.8 Hours
Gallbladder cancer (GBC) is the most common and aggressive subtype of biliary tract cancer (BTC) and has a poor prognosis. A newly developed regimen of gemcitabine, cisplatin, and durvalumab shows promise for the treatment of advanced BTC. However, the efficacy of this treatment for GBC remains unclear.
In this report, we present a case in which the triple-drug regimen exhibited marked effectiveness in treating locally advanced GBC, thus leading to a long-term survival benefit. A 68-year-old man was diagnosed with locally advanced GBC, which rendered him ineligible for curative surgery. Following three cycles of therapy, a partial response was observed. After one year of combined therapy, a clinical complete response was successfully achieved. Subsequent maintenance therapy with durvalumab monotherapy resulted in a disease-free survival of 9 months for the patient. The patient experienced tolerable toxicities of reversible grade 2 nausea and fatigue. Tolerable adverse events were observed in the patient throughout the entirety of the treatment.
The combination of gemcitabine and cisplatin chemotherapy with durvalumab was proven to be an effective treatment approach for advanced GBC, with manageable adverse events. Further research is warranted to substantiate the effectiveness of the combined regimen in the context of GBC.
Core Tip: This study presents a significant case of a patient with locally advanced gallbladder cancer (GBC) who achieved a clinical complete response following treatment with a novel regimen combining gemcitabine, cisplatin, and durvalumab (GC-D). Despite the notorious resistance of GBC to conventional therapies, the positive outcomes observed in this case suggest potential benefits of immunotherapy in this context. These findings highlight the need for further research to validate the efficacy of the GC-D regimen and to explore its implications for future treatment protocols in GBC.